Renin–angiotensin system inhibitors reduce cardiovascular mortality in hypertensive patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: insights from the EffecTAVI registry
暂无分享,去创建一个
G. de Simone | P. Cirillo | A. Franzone | C. Mancusi | Luca Bardi | M. Avvedimento | Andrea Mariani | D. Angellotti | D. Castiello | G. Esposito | C. Basile | N. De Luca | R. Manzo
[1] Jinyu Huang,et al. The clinical outcomes of reni-angiotensin system inhibitors for patients after transcatheter aortic valve replacement: A systematic review and meta-analysis , 2022, Frontiers in Cardiovascular Medicine.
[2] C. Mancusi,et al. New Evidence About Aortic Valve Stenosis and Cardiovascular Hemodynamics , 2022, High Blood Pressure & Cardiovascular Prevention.
[3] A. Franzone,et al. Arterial Hypertension in Aortic Valve Stenosis: A Critical Update , 2021, Journal of clinical medicine.
[4] R. Piccolo,et al. Extent of Cardiac Damage and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation , 2021, Journal of clinical medicine.
[5] S. Kapadia,et al. Renin‐Angiotensin System Blockade in Aortic Stenosis: Implications Before and After Aortic Valve Replacement , 2020, Journal of the American Heart Association.
[6] K. Laugwitz,et al. Dose Dependent Effect of Renin Angiotensin System Blockade Following Transcatheter Aortic Valve Replacement. , 2020, The Canadian journal of cardiology.
[7] J. Carroll,et al. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement , 2018, JAMA.
[8] W. Spiering,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.
[9] B. García del Blanco,et al. Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study , 2018, BMJ Open.
[10] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[11] J. Leipsic,et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. , 2016, European heart journal.
[12] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.
[13] P. Pibarot,et al. Impact of hypertension and renin–angiotensin system inhibitors in aortic stenosis , 2013, European journal of clinical investigation.
[14] G. de Simone,et al. Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors , 2012, Journal of hypertension.
[15] J. Després,et al. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves , 2011, European journal of clinical investigation.
[16] J. Pepper,et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.
[17] P. Kovanen,et al. Aortic valve stenosis: an active atheroinflammatory process , 2007, Current opinion in lipidology.
[18] W. Wijns. European Association of Percutaneous Cardiovascular Interventions (EAPCI). , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[19] K. Orito,et al. Cardiac remodeling and angiotensin II-forming enzyme activity of the left ventricle in hamsters with chronic pressure overload induced by ascending aortic stenosis. , 2006, The Journal of veterinary medical science.
[20] M. Mäyränpää,et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.
[21] R Alagesan,et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.
[22] Arantxa González,et al. Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.
[23] H. Rimington,et al. Aortic stenosis and ACE inhibitors , 1998, The Lancet.
[24] OUP accepted manuscript , 2022, European Heart Journal - Cardiovascular Pharmacotherapy.
[25] G. Mancia,et al. Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis: Relationship with all-cause mortality. , 2019, International journal of cardiology.
[26] C. Andersson,et al. Is the use of renin–angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? A systematic review and meta-analysis , 2017, European heart journal. Cardiovascular pharmacotherapy.